p19Arf limits primary vitreous cell proliferation driven by PDGF-B

Nida S. Iqbal, Caitlin C. Devitt, Caroline Y. Sung, Stephen X. Skapek

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Arf encodes an important tumor suppressor, p19Arf, which also plays a critical role to control hyperplasia in the primary vitreous during mouse eye development. In the absence of Arf, mice are born blind and display a phenotype closely mimicking severe forms of the human eye disease, persistent hyperplastic primary vitreous (PHPV). In this report, we characterize p19Arf expression in perivascular cells that normally populate the primary vitreous and express the Arf promoter. Using a new ex vivo model, we show that these cells respond to exogenous Tgfβ, despite being isolated at a time when Tgfβ has already turned on the Arf promoter. Treatment of the cells with PDGF-B ligand doubles the population of cells in S-phase and ectopic expression of Arf blunts that effect. We show this effect is mediated through Pdgfrβ as expression of Arf represses expression of Pdgfrβ mRNA and protein to approximately 60%. p53 is not required for Arf-dependent blockade of PDGF-B driven proliferation and repression of Pdgfrβ protein as ectopic expression of Arf is still able to inhibit the 2-fold increase in the S-phase fraction of cells upon treatment with PDGF-B. Finally, induction of mature miR-34a, a microRNA previously identified to be regulated by p19Arf does not depend on p53 while the expression of the primary transcript does require p53. These data corroborate that, as in vivo, p19Arf functions to inhibit PDGF-B driven proliferation ex vivo.

Original languageEnglish (US)
Pages (from-to)224-229
Number of pages6
JournalExperimental Eye Research
Volume145
DOIs
StatePublished - Apr 1 2016

Fingerprint

Cell Proliferation
S Phase
Persistent Hyperplastic Primary Vitreous
Eye Diseases
MicroRNAs
Hyperplasia
Proteins
Ligands
Phenotype
Messenger RNA
Population
Neoplasms
Ectopic Gene Expression

Keywords

  • miR-34a
  • p19
  • p53
  • Pdgfrβ
  • Perivascular cells
  • PHPV
  • Primary vitreous

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

p19Arf limits primary vitreous cell proliferation driven by PDGF-B. / Iqbal, Nida S.; Devitt, Caitlin C.; Sung, Caroline Y.; Skapek, Stephen X.

In: Experimental Eye Research, Vol. 145, 01.04.2016, p. 224-229.

Research output: Contribution to journalArticle

Iqbal, Nida S. ; Devitt, Caitlin C. ; Sung, Caroline Y. ; Skapek, Stephen X. / p19Arf limits primary vitreous cell proliferation driven by PDGF-B. In: Experimental Eye Research. 2016 ; Vol. 145. pp. 224-229.
@article{838eb119c1c34e58b3bc5154401be671,
title = "p19Arf limits primary vitreous cell proliferation driven by PDGF-B",
abstract = "Arf encodes an important tumor suppressor, p19Arf, which also plays a critical role to control hyperplasia in the primary vitreous during mouse eye development. In the absence of Arf, mice are born blind and display a phenotype closely mimicking severe forms of the human eye disease, persistent hyperplastic primary vitreous (PHPV). In this report, we characterize p19Arf expression in perivascular cells that normally populate the primary vitreous and express the Arf promoter. Using a new ex vivo model, we show that these cells respond to exogenous Tgfβ, despite being isolated at a time when Tgfβ has already turned on the Arf promoter. Treatment of the cells with PDGF-B ligand doubles the population of cells in S-phase and ectopic expression of Arf blunts that effect. We show this effect is mediated through Pdgfrβ as expression of Arf represses expression of Pdgfrβ mRNA and protein to approximately 60{\%}. p53 is not required for Arf-dependent blockade of PDGF-B driven proliferation and repression of Pdgfrβ protein as ectopic expression of Arf is still able to inhibit the 2-fold increase in the S-phase fraction of cells upon treatment with PDGF-B. Finally, induction of mature miR-34a, a microRNA previously identified to be regulated by p19Arf does not depend on p53 while the expression of the primary transcript does require p53. These data corroborate that, as in vivo, p19Arf functions to inhibit PDGF-B driven proliferation ex vivo.",
keywords = "miR-34a, p19, p53, Pdgfrβ, Perivascular cells, PHPV, Primary vitreous",
author = "Iqbal, {Nida S.} and Devitt, {Caitlin C.} and Sung, {Caroline Y.} and Skapek, {Stephen X.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.exer.2016.01.004",
language = "English (US)",
volume = "145",
pages = "224--229",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - p19Arf limits primary vitreous cell proliferation driven by PDGF-B

AU - Iqbal, Nida S.

AU - Devitt, Caitlin C.

AU - Sung, Caroline Y.

AU - Skapek, Stephen X.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Arf encodes an important tumor suppressor, p19Arf, which also plays a critical role to control hyperplasia in the primary vitreous during mouse eye development. In the absence of Arf, mice are born blind and display a phenotype closely mimicking severe forms of the human eye disease, persistent hyperplastic primary vitreous (PHPV). In this report, we characterize p19Arf expression in perivascular cells that normally populate the primary vitreous and express the Arf promoter. Using a new ex vivo model, we show that these cells respond to exogenous Tgfβ, despite being isolated at a time when Tgfβ has already turned on the Arf promoter. Treatment of the cells with PDGF-B ligand doubles the population of cells in S-phase and ectopic expression of Arf blunts that effect. We show this effect is mediated through Pdgfrβ as expression of Arf represses expression of Pdgfrβ mRNA and protein to approximately 60%. p53 is not required for Arf-dependent blockade of PDGF-B driven proliferation and repression of Pdgfrβ protein as ectopic expression of Arf is still able to inhibit the 2-fold increase in the S-phase fraction of cells upon treatment with PDGF-B. Finally, induction of mature miR-34a, a microRNA previously identified to be regulated by p19Arf does not depend on p53 while the expression of the primary transcript does require p53. These data corroborate that, as in vivo, p19Arf functions to inhibit PDGF-B driven proliferation ex vivo.

AB - Arf encodes an important tumor suppressor, p19Arf, which also plays a critical role to control hyperplasia in the primary vitreous during mouse eye development. In the absence of Arf, mice are born blind and display a phenotype closely mimicking severe forms of the human eye disease, persistent hyperplastic primary vitreous (PHPV). In this report, we characterize p19Arf expression in perivascular cells that normally populate the primary vitreous and express the Arf promoter. Using a new ex vivo model, we show that these cells respond to exogenous Tgfβ, despite being isolated at a time when Tgfβ has already turned on the Arf promoter. Treatment of the cells with PDGF-B ligand doubles the population of cells in S-phase and ectopic expression of Arf blunts that effect. We show this effect is mediated through Pdgfrβ as expression of Arf represses expression of Pdgfrβ mRNA and protein to approximately 60%. p53 is not required for Arf-dependent blockade of PDGF-B driven proliferation and repression of Pdgfrβ protein as ectopic expression of Arf is still able to inhibit the 2-fold increase in the S-phase fraction of cells upon treatment with PDGF-B. Finally, induction of mature miR-34a, a microRNA previously identified to be regulated by p19Arf does not depend on p53 while the expression of the primary transcript does require p53. These data corroborate that, as in vivo, p19Arf functions to inhibit PDGF-B driven proliferation ex vivo.

KW - miR-34a

KW - p19

KW - p53

KW - Pdgfrβ

KW - Perivascular cells

KW - PHPV

KW - Primary vitreous

UR - http://www.scopus.com/inward/record.url?scp=84961327775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961327775&partnerID=8YFLogxK

U2 - 10.1016/j.exer.2016.01.004

DO - 10.1016/j.exer.2016.01.004

M3 - Article

VL - 145

SP - 224

EP - 229

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

ER -